Items tagged with Drug-resistant TB
NovoBiotic reports the discovery of teixobactin, a new antibiotic without detectable resistance (post)
No resistant mutants of either S. aureus or Mycobacterium tuberculosis could be generated
Five more drugs get local clinical trial waiver for importing, marketing in India (post)
The Union Health Ministry accorded permission to five more drugs—chronic hepatitis C drug Sofosbuvir, prostrate cancer drug Enzalutamide, cutaneous T-cell lymphoma drug Vorinostat, pulmonary tuberculosis drug Bedaquiline tablets 100 mg and Haemophilia drug Rixubis—for importing and marketing in India without local clinical trial on Indian population.
Drug-resistance mechanisms and tuberculosis drugs (post)
Bedaquiline and delamanid, novel classes of anti-tuberculosis drugs, have been recently approved for the treatment of multidrug-resistant tuberculosis.
White House plans big 2016 budget ask to fight antibiotic resistance (post)
In advance of the 2016 budget proposal, the White House has tipped its hand on one big priority: the fight against antibiotic resistance. A fact sheet released today describes how President Barack Obama plans to double the government's investment in combating the mounting public health crisis of drug-resistant infections by spreading roughly $1.2 billion in funding across several federal agencies.
Good outcomes within the National Bedaquiline Clinical Access programme in South Africa (post)
The South African Bedaquiline Clinical Access Programme showed good interim outcomes in people with drug resistant tuberculosis (DR-TB), according to data presented at the 45th Union Conference on Lung Health.
Problems giving current second line TB drugs to children (post)
Results from a survey presented at 45th Union World Conference on Lung Health reveal an urgent need for child appropriate formulations of second line TB drugs. [1]
Indian government backs SIRTURO® (bedaquiline) for treatment of multidrug-resistant tuberculosis (MDR-TB) (post)
29 January 2015 - New Delhi, India -- On January 14, 2015, The Drugs Controller General of India (DCGI) approved SIRTURO® (bedaquiline) for use in adults (>18 years) as part of combination therapy of pulmonary tuberculosis due to multidrug-resistant Mycobacterium tuberculosis (MTR-TB), when an effective treatment regimen cannot otherwise be provided.
New antibiotic to treat multidrug-resistant tuberculosis (MDR-TB) receives approval in Peru (post)
29 January 2015 -- Lima, Peru - Pulmonary multidrug-resistant tuberculosis (MDR-TB) causes the deaths of over 200,000 people globally each year. With an estimated 2,000 cases in 2013, Peru has the highest prevalence of MDR-TB in Latin America and the Caribbean and cases have significantly increased since 2009 . On December 13th 2014, Janssen, the pharmaceutical affiliate of Johnson & Johnson, received approval for SIRTURO® (bedaquiline) from the Peruvian health authorities.
Lamprene effectively treats MDR-TB (post)
Adding Lamprene to current tuberculosis therapy demonstrated higher treatment success than standard treatment alone in treating multidrug-resistant tuberculosis, researchers in China have found.
Page 12 of 117 · Total posts: 0
←First 11 12 13 Last→